Tolerance of the introduction of post-immunotherapy targeted therapy in NSCLC patients with addictive targetable mutations (EGFR, BRAF, HER2, MET exon 14 or translocation ALK, ROS1, RET or NTRK) and included in the IMAD, IMAD2 , IMAD3, IMMUNOADDICT and ESCKEYP trials